FDA Discusses Social Media and the Life Sciences Industry

As many of you know, the life sciences industry, one of the most highly regulated industries of the economy has been hesitant and reluctant to embrace social media to reach out to patients, physicians

By Clifford M on Mar 17, 2009

As many of you know, the life sciences industry, one of the most highly regulated industries of the economy has been hesitant and reluctant to embrace social media to reach out to patients, physicians and the lay public. This is because the US Food and Drug Administration, specifically Division for Drug Marketing, Advertising and Communications (DDMAC), has been mute on the subject and hasnt issue one iota of guidance on the use of social media in the pharmaceutical, biotechnology or medical devices/diagnostic industries.

Mark Senak, a regulatory affairs lawyer and owner of the blog eyeonfda.com, invited Dr. Jean Ah Kang, Special Assistant at DDMAC in charge of Web 2.0 policy development to talk about FDAs views and ideas about social media and its use in the life sciences industry. Listening to the 15 min podcast would be, according to Mark, time well spent for social media advocates in the pharmaceutical, biotechnology and medical devices/diagnostics sectors.

Hat tip and much love to Mark who wrote BTW, I absolutely expect waves of love for this (the podcast)."